Literature DB >> 1564416

Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells.

M J Reed1, N G Coldham, S R Patel, M W Ghilchik, V H James.   

Abstract

Gross cystic breast disease is a common benign disease which may be associated with an increased risk for breast cancer. Breast cyst fluid (BCF) contains many steroids, peptide growth factors and proteins. We have now identified interleukin-1 (IL-1) and IL-6 in BCF by specific radioimmunoassays. Concentrations of IL-1 were similar in BCF with low or high Na+/K+ ratios (ratio less than 3 vs greater than 3; 357 +/- 72 pg/ml vs 308 +/- 126 pg/ml). In contrast, IL-6 concentrations were significantly higher (P less than 0.01) in BCF with a Na+/K+ ratio greater than 3 (2.75 +/- 2.34 ng/ml) compared with BCF with a low electrolyte ratio (0.21 +/- 0.09 ng/ml). BCF (10%, v/v) stimulated aromatase activity when added to dexamethasone stimulated breast tumour-derived fibroblasts and there was a significant correlation between the stimulation of aromatase activity and BCF Na+/K+ ratio (r = 0.95, P less than 0.001). A significant correlation was also found between stimulation of aromatase activity and concentration of IL-6 in BCF (r = 0.80, P less than 0.01) but not IL-1 concentration (r = -0.39, not significant). Addition of IL-1 or IL-6 (50 ng/ml) to fibroblasts stimulated aromatase activity but was associated with a small (20%) decrease in cell growth. It is concluded that IL-6 may have an important role in regulating aromatase activity in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1564416     DOI: 10.1677/joe.0.132r005

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  10 in total

1.  Increased risk of orofacial clefts associated with maternal obesity: case-control study and Monte Carlo-based bias analysis.

Authors:  Marni Stott-Miller; Carrie L Heike; Mario Kratz; Jacqueline R Starr
Journal:  Paediatr Perinat Epidemiol       Date:  2010-09       Impact factor: 3.980

Review 2.  Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.

Authors:  Priya Bhardwaj; CheukMan C Au; Alberto Benito-Martin; Heta Ladumor; Sofya Oshchepkova; Ruth Moges; Kristy A Brown
Journal:  J Steroid Biochem Mol Biol       Date:  2019-03-06       Impact factor: 4.292

Review 3.  Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease.

Authors:  Stevan P Tofovic
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

Review 4.  Sex Differences, Estrogen Metabolism and Signaling in the Development of Pulmonary Arterial Hypertension.

Authors:  Yanan Sun; Shreya Sangam; Qiang Guo; Jian Wang; Haiyang Tang; Stephen M Black; Ankit A Desai
Journal:  Front Cardiovasc Med       Date:  2021-09-10

5.  Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.

Authors:  Julio E Celis; José M A Moreira; Irina Gromova; Teresa Cabezón; Pavel Gromov; Tao Shen; Vera Timmermans; Fritz Rank
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

Review 6.  The role of aromatase in breast tumors.

Authors:  M J Reed
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 7.  Weighing the Risk: effects of Obesity on the Mammary Gland and Breast Cancer Risk.

Authors:  Lauren E Hillers-Ziemer; Lisa M Arendt
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-06-09       Impact factor: 2.673

Review 8.  The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer.

Authors:  Atul Purohit; Simon P Newman; Michael J Reed
Journal:  Breast Cancer Res       Date:  2002-01-14       Impact factor: 6.466

9.  In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Authors:  Anne E Lykkesfeldt; Katrine L Henriksen; Birgitte B Rasmussen; Hironobu Sasano; Dean B Evans; Susanne Møller; Bent Ejlertsen; Henning T Mouridsen
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

10.  Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts.

Authors:  A Purohit; A Singh; M W Ghilchik; O Serlupi-Crescenzi; M J Reed
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.